ERBC WAS BORN ON 1ST NOVEMBER 2019, WHEN CERB (FRANCE) ACQUIRED THE TOXICOLOGY ACTIVITIES FROM RTC (ITALY). BY MERGING THE COMPLEMENTARY PORTFOLIOS OF PHARMACOLOGY AND TOXICOLOGY, A NEW FULL SERVICE PROVIDER WAS CREATED AND RENAMED TO ERBC. ERBC IS A EUROPEAN LEADER IN NON-CLINICAL STUDIES, OFFERING TO HEALTHCARE AND CHEMICAL PROFESSIONALS A COMPREHENSIVE RANGE OF EXPERIMENTAL CAPABILITIES, PRECLINICAL MODELS, REGULATORY PRE-IND PACKAGE AND CONSULTANCY SERVICES TO DE-RISK INNOVATION AND IMPROVE R&D PRODUCTIVITY.
Based in Baugy (France) and Roma (Italy), ERBC provides all services from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, also benefiting from a world class academic and private network.
Every year, study reports from our two Centers are successfully used in support of market authorizations and new product approval submissions around the world, including the European (EMA, ECHA), US (FDA and EPA) and Japanese (MHLW and MAFF) regulatory authorities.
Investment in outstanding scientific and technical manpower, high-tech equipment and facilities are crucial cornerstones of our sound and organic growth. The quality and reliability of our performance are reflected by the many ongoing and long-lasting collaborations we maintain with leading international pharmaceutical and chemical companies.
ERBC is deeply engaged in animal ethics and welfare. ERBC supports the Basel Declaration, respects the 3Rs concept and continually improves its tools and procedures to maximize the balance between the benefit for health and the animal well-being.